Literature DB >> 18762514

First successful bone marrow transplantation for X-linked chronic granulomatous disease by using preimplantation female gender typing and HLA matching.

Janine Reichenbach1, Hilde Van de Velde, Martine De Rycke, Cathérine Staessen, Peter Platteau, Patricia Baetens, Tayfun Güngör, Hulya Ozsahin, Franziska Scherer, Ulrich Siler, Reinhard A Seger, Inge Liebaers.   

Abstract

Allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen (HLA)-identical donor is currently the only proven curative treatment for chronic granulomatous disease. Hematopoietic stem cell transplantation with alternative donors is associated with higher morbidity and mortality. Therefore, we performed in vitro fertilization and preimplantation HLA matching combined with female sexing for hematopoietic stem cell transplantation in chronic granulomatous disease. Ethical and psychological issues were considered carefully. We used in vitro fertilization with X-enriched spermatozoa followed by preimplantation genetic diagnosis to identify female HLA-genoidentical embryos in a family in need of a suitable donor for their boy affected with severe X-linked chronic granulomatous disease. Two preimplantation genetic diagnosis cycles were performed in the family. In the second cycle, 2 HLA-genoidentical female embryos were transferred and a singleton pregnancy was obtained, resulting in the birth of an unaffected girl at term. Because of insufficient cell numbers in the cord-blood source, conventional hematopoietic stem cell transplantation had to be performed at 12 months of age of the donor and 5 years of age of the recipient and resulted in complete stable donor chimerism and immunologic reconstitution up to 25 months post-hematopoietic stem cell transplantation. Hematopoietic stem cell transplantation after in vitro fertilization and combined female sexing and HLA matching offers a new and relatively rapid therapeutic option for patients with X-linked primary immunodeficiency such as chronic granulomatous disease who need hematopoietic stem cell transplantation but lack an HLA-genoidentical donor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762514     DOI: 10.1542/peds.2008-0123

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

2.  Preimplantation genetic testing with HLA matching: from counseling to birth and beyond.

Authors:  M De Rycke; A De Vos; F Belva; V Berckmoes; M Bonduelle; A Buysse; K Keymolen; I Liebaers; J Nekkebroeck; P Verdyck; W Verpoest
Journal:  J Hum Genet       Date:  2020-02-27       Impact factor: 3.172

3.  Experience of preimplantation genetic diagnosis with HLA matching at the University Hospital Virgen del Rocío in Spain: technical and clinical overview.

Authors:  Raquel María Fernández; Ana Peciña; Maria Dolores Lozano-Arana; Beatriz Sánchez; Jordi Guardiola; Juan Carlos García-Lozano; Salud Borrego; Guillermo Antiñolo
Journal:  Biomed Res Int       Date:  2014-04-24       Impact factor: 3.411

4.  Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection.

Authors:  Philipp Schwenkenbecher; Alexandra Neyazi; Frank Donnerstag; Felix C Ringshausen; Roland Jacobs; Matthias Stoll; Philip Kirschner; Florian Peter Länger; Emil Valizada; Stefan Gingele; Florian Wegner; Kurt-Wolfram Sühs; Martin Stangel; Thomas Skripuletz
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

5.  Novel one-step multiplex PCR-based method for HLA typing and preimplantational genetic diagnosis of β-Thalassemia.

Authors:  Raquel M Fernández; Ana Peciña; Maria Dolores Lozano-Arana; Juan Carlos García-Lozano; Salud Borrego; Guillermo Antiñolo
Journal:  Biomed Res Int       Date:  2013-04-04       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.